IBEX Technologies Inc. (TSX: IBT) today announced that it has completed its fifth and final payment to former HDM Diagnostics & Imaging Inc. (”HDM”) shareholders to retain the exclusive rights to its portfolio of arthritis biomarkers. In fulfilling its final payment, IBEX issued 1,633,186 common shares, valued at $200,000 (as at July 13, 2007). After giving effect to the fifth-year payment to …
More: continued here